Brad Bolzon, Ph.D., is a Managing Director and chairman of the investment team at Versant. Brad combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. His track record consists of successive outlier returns including Amira ($475M sale), Okairos ($325M sale), Speedel ($880M sale), Quanticel ($485M sale), Novira (price not disclosed), Flexion ($900M+ mkt cap, 2014 IPO), Crispr ($2B+ mkt cap, 2016 IPO), Biotie ($363M sale) and he continues to manage several other promising investments. Brad is the architect of Versant’s investment strategy.
Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances at Roche. Under his leadership, Roche established alliances with over 75 venture-backed biotech companies worldwide and transformed its R&D pipeline into an industry leader. Prior to that, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs and business development. He earned Master of Science and Ph.D. degrees in Pharmacology from the University of Toronto.